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Azidothymidine and Interferon-a Induce Apoptosis in Herpesvirusassociated Lymphomas1
Richard K. Lee,2 Jian-Ping Cai,2 Vadim Deyev, Parkash S. Gill, Lisa Cabral, Charles Wood, Ram P. Agarwal,
Wenle Xia, Lawrence H. Boise, Eckhard Podack, and William J. Harrington, Jr.3
Department of Microbiology and Immunology [R. K. L., V. D., L. H. B., E. P.] and Division of Hematology/Oncology, Department of Medicine [J-P. C., L. C., R. P. A., W. X.,
W. J. H.], University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida 33136; Departments of Medicine and Pathology, University of
Southern California, Los Angeles, California 90033 [P. S. G.]; and Department of Microbiology and Immunology, University of Nebraska, Lincoln, Nebraska 68588 [C. W.]

ABSTRACT
Lymphoproliferative diseases that occur in immunocompromised patients are frequently associated with herpesviruses. These patients often
fare poorly after treatment with conventional chemotherapy. We reported
previously that patients with AIDS-related Burkitt’s lymphoma (BL)
responded to parenteral azidothymidine (AZT) and IFN-a. We found that
EBV-positive lymphoma cells derived from these patients cultured with
AZT express CD95 and undergo apoptosis. AZT-mediated apoptosis was
caspase dependent and occurred despite Fas receptor blockade. In contrast, EBV-negative lymphomas were resistant to AZT-induced apoptosis,
as were EBV-positive lymphomas that expressed high levels of bcl-2.
Primary effusion lymphoma (PEL) cell lines infected with human herpesvirus type 8 required IFN-a to potentiate AZT-induced apoptosis. IFN-a
did not up-regulate CD95 in BL or PEL but did induce expression of the
death receptor ligand, CD95 ligand. AZT-sensitive lymphomas also accumulated significantly higher intracellular AZT monophosphate than did
resistant lymphomas. Our data demonstrated distinct apoptotic responses
to AZT and IFN-a in herpesvirus-associated lymphomas. EBV-positive
BL cells that expressed low BCL-2 levels were sensitive to AZT alone;
PEL cells required the addition of IFN-a to enhance apoptosis, and
EBV-negative lymphomas were insensitive to both agents. AZT-sensitive
BL cells transfected with BCL-2 became resistant. Susceptibility to antivirus-mediated apoptosis may be exploited to improve the therapy of
certain herpesvirus-associated lymphomas.

mas. BL typically contains reciprocal translocations that juxtapose the
c-myc gene near an immunoglobulin promoter. Large cell diffuse or
immunoblastic lymphoma contains c-myc rearrangements less frequently but often carries mutations in BCL-6. BCL-2 overexpression
is also more common in AIDS-related large cell types than BL (5–9).
PEL usually presents as a malignant effusion without an apparent
tumor mass in HIV-infected patients (4). These cellular and molecular
characteristics, along with the different epidemiological profiles of
AIDS NHLs, indicate that these tumors are biologically distinct.
This study of AIDS NHL primary patient tumor isolates, cell lines
established from these patients, and published cell lines demonstrates
that EBV-positive lymphomas and HHV-8-positive PEL cell lines are
susceptible to AZT or AZT/IFN-a-mediated apoptosis. Apoptosis was
associated with up-regulation of death receptor or death receptor
ligands and activation of caspases. In contrast, AIDS B-cell lymphomas that expressed high levels of BCL-2 and EBV-negative lymphomas were resistant to AZT or AZT and IFN-a. These data indicate that
AZT and IFN-a-mediated apoptosis may be specific for certain herpes
virus-associated NHLs.
MATERIALS AND METHODS

Clinical Samples and Establishment of Primary Cell Lines. This study
was performed under the guidelines of the University of Miami Institutional
Review Board, where there is an ongoing protocol for AZT and IFN-a
INTRODUCTION
induction therapy for AIDS-related BL and PEL. All lymphomas studied were
Lymphomas that occur in immunocompromised individuals are classified by independent reviews from two hematopathologists. Lymphomas
classified as Burkitt’s met criteria for small noncleaved cell lymphomas,
frequently associated with herpesviruses (1). AIDS NHLs4 account
Burkitt’s type, according to the Working Formulation (10). Primary tumor
for a large percentage of these cases in the United States. Approxi- isolates, cell lines established from AIDS NHL patients, and lines obtained
mately 30% of AIDS NHLs are categorized as Burkitt’s type, and from the American Type Tissue Culture Collection (Bethesda, MD) were used
most of the rest are classified as diffuse or IBLs and primary central for this study.
nervous system lymphomas (2, 3). A recently identified subtype of
Primary Patient Isolates. BL-3 was derived from a patient with AIDSAIDS NHL is PEL associated with HHV-8 (4). AIDS BL commonly related, EBV-positive L3 (Burkitt’s type) leukemia who responded to treatoccurs in the setting of less severe immunosuppression than IBL, ment with AZT and IFN-a (11). Flow cytometry of PBMCs demonstrated that
PEL, or primary cell nervous system lymphoma but grows more 90% of circulating mononuclear cells were CD19 positive. These cells were
rapidly, resulting in severe metabolic abnormalities related to tumor positive by PCR for EBV. We were unable to establish BL-3 as a cell line, and
cytogenetics were not performed.
lysis syndrome.
BL-5 was derived from a diagnostic axillary node biopsy of a patient with
These categories of AIDS lymphoma are associated with certain
AIDS-related BL who responded to AZT and IFN-a therapy. Cells from
molecular profiles. EBV is detected in BL in about 30% of cases and residual tissue of this specimen were cultured and after ;40 passages are now
in the majority of large cell lymphomas and immunoblastic lympho- an established line. The BL-5 line is EBV positive (by PCR) and carries the
most common c-myc 8;14 translocation.
Received 3/4/99; accepted 9/13/99.
SM-1 is a line established from a lymphomatous pericardial effusion from
The costs of publication of this article were defrayed in part by the payment of page
an AIDS patient. Flow cytometry demonstrated that 90% of these cells are
charges. This article must therefore be hereby marked advertisement in accordance with
CD19 positive. SM-1 has been established in culture for over 5 months and 30
18 U.S.C. Section 1734 solely to indicate this fact.
1
passages. SM-1 is EBV positive and HHV-8 negative (by PCR) and carries an
Supported by Grants U01-CA-70058, R29-CA-77837, R01-CA-57904, and K12-CA8;14 translocation.
77824 (to R.K.L.) from the NIH.
2
These authors contributed equally to this work.
IBL-3 is a primary tumor cell culture of a malignant lymphomatous effusion
3
To whom requests for reprints should be addressed, at University of Miami School
derived from a patient unresponsive to AZT and IFN-a. The tumor was
of Medicine, Sylvester Comprehensive Cancer Center, Room 3400 (D8-4), 1475 Northhistopathologically classified as an IBL. It was negative for c-myc expression
west 12th Avenue, Miami, FL 33136. Phone: (305) 243-4994; Fax: (305) 243-5239;
by Western blot. PCR analysis of the tumor was positive for EBV and negative
E-mail: wharring@mednet.med.miami.edu.
4
The abbreviations used are: AIDS NHL, AIDS related non-Hodgkin’s lymphoma;
for HHV-8. The tumor was not established as a continuous line.
PEL, primary effusion lymphoma; HHV, human herpesvirus; AZT, azidothymidine; BL,
IBL-4 was derived from a diagnostic thoracentesis performed on a patient
Burkitt’s lymphoma; IBL, immunoblastic large cell lymphoma; PBMC, peripheral blood
unresponsive to AZT and IFN-a with AIDS-related IBL. The tumor has been
mononuclear cell; CD95L, CD95 ligand; LDH, lactate dehydrogenase; PARP, poly(ADPestablished as a cell line (40 passages over 6 months). IBL-4 is CD19 positive,
ribose) polymerase; LMP, latent membrane protein.
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contains a balanced 2;8 translocation, and is EBV positive and HHV-8 negative by PCR.
BL-6 is a primary tumor cell culture obtained from a HIV patient with
EBV-negative BL with circulating L3 lymphoblasts. Flow cytometry of the
primary tumor specimen demonstrated that 90% of cells were CD19 positive.
This patient was unresponsive to AZT and IFN-a. Cytogenetic analysis of the
primary tumor cells was not done, and we were unable to establish a cell line.
Established Cell Lines. P3HR-1, Namalwa, and Daudi are EBV-positive
lymphoma lines established from patients with endemic BL, and all contain the
c-myc translocation. BJAB, Ramos, and D6 are EBV-negative B-cell lymphoma lines derived from HIV-negative patients. H9, a T-cell line, and B95-8,
a marmocet line infected with EBV, were also used for our experiments.
BCBL-1, BC-1, and BC-3 are lines developed from PEL patients. BCBL-1 and
BC-3 are infected with HHV-8; BC-1 also contains EBV (12). These lines
were obtained from the American Type Culture Collection.
All tumor cells and lines were maintained in culture with 10% heatinactivated FCS in Iscove’s modified Dulbecco’s media (Life Technologies,
Inc., Grand Island, NY).
Reagents and Antibodies. The caspase protease inhibitors, BocD-fmk and
zVAD-fmk, were purchased from Enzyme Systems Products (Dublin, CA) and
prepared in anhydrous DMSO. For apoptosis inhibition assays, caspase inhibitors were added to cells prior to drug treatment or addition of CD95 agonist
antibody (clone DX-2) from PharMingen (San Diego, CA).
Immunostaining of cells for CD95 expression was performed with mouse
anti-human CD95 FITC or CD95 PE (clone DX2) from PharMingen. AntiCD95 blocking antibody (clone ZB4) was purchased from Coulter Immunotech (Miami, FL).
Cytotoxicity Assays. Target cell lysis was assessed by 51Cr release assay.
Briefly, 1 3 106 target cells were incubated with 200 mCi of Na2-51CrO4
(Amersham, Arlington Heights, IL) for 1 h, washed, and plated into roundbottomed 96-well tissue plates at 1 3 104 target cells/well in triplicate. The
target cells were incubated with effector cells at the indicated E:T ratios in a
total volume of 200 ml of media for 4 h at 37°C in a CO2 incubator. In assays
of cytotoxicity against CD95-expressing targets, we used as effector cells the
murine lymphoma line EL-4, stably transfected with CD95 ligand (CD95L;
EL4-mFL). Cytotoxicity assay supernatant (100 ml) was gamma counted, and
the percentage of specific lysis was calculated by subtraction of spontaneous
lysis from target cell lysis divided by the difference between complete and
spontaneous lysis (target cells incubated with media alone). Complete target
cell 51Cr release was induced by total cell lysis with HCl. Cytotoxicity assays
were performed in triplicate per experiment and repeated at least twice.
Transfection of BL-5 with BCL-2. BCL-2 transfectants were prepared as
described previously (13). BL-5 cells were transfected by electroporation with
the pSFFV-NEO plasmid containing BCL-2a in transcriptional orientation. As
a control, transfection was also performed with the pSFFV-NEO plasmid
without an insert. Cells were cultured in medium containing G418 (1 mg/ml).
Transfectants with acquisition of neomycin resistance were selected. Singlecell clones were generated by limiting dilution. The expression of BCL-2 in
selected single cell clones was confirmed by Western blot. The selected clone,
BL-5-BCL-2, expressed similar baseline levels of CD95 compared with BL-5
cells and BL-5-neo controls.
Flow Cytometry. Antibody staining was performed on one million cells
for each conjugated primary antibody. FITC or PE-conjugated mouse antihuman CD95 antibody (DX-2; PharMingen) or isotype control antibodies were
used according to the manufacturer’s recommendations, at a concentration of
5 mg/ml, in PBS/0.5% albumin/0.1% sodium azide (PBA) in 50 ml. Stained
cells were placed on ice for 30 min, washed twice, and then immediately
analyzed on a Becton Dickinson FACScan flow cytometer (Mountain View,
CA). Analysis of CD95 expression levels was performed on live cells gated by
forward and side scatter.
Apoptosis was assayed with propidium iodide/annexin V staining. For
propidium iodide/annexin V-FITC staining of apoptosis, cells were washed
with annexin V FACS buffer (HBSS buffer with calcium, magnesium, sodium
azide, and 0.5% BSA) and incubated on ice with a 1:30 dilution of annexin
V-FITC (Caltag Laboratories, Burlingame, CA) for 30 min and washed in
FACS buffer. Prior to FACS analysis, propidium iodide at 5 mg/ml (Sigma
Chemical Co., St. Louis, MO) was added to the cells and gently mixed. Stained
cells were immediately analyzed by FACS.

Semiquantitative Reverse Transcription-PCR and ELISA for CD95L.
Total RNA was prepared according to the manufacturer’s specifications
(RNAeasy; Qiagen, Valencia, CA) from aliquots of 106 cells. One mg of total
RNA was resuspended in 12.5 ml of RNase free water, and 1 ml of oligo(dT)
was added, and the mixture was heated for 2 min at 90°C. cDNA was
synthesized in a reaction mixture (6.5 ml) containing 1 ml of Moloney murine
leukemic virus reverse transcriptase (200 u/ml), 1 ml of deoxynucleotide
triphosphate mixture (10 mM each), 0.5 ml of RNase inhibitor (40 u/ml), 25 mM
Tris (pH 8.3), 37 mM KCl, 1.5 mM MgCl, and 5 mM DTT. The tubes were
incubated for 1 h, and the reaction was stopped by incubation at 94°C for 5
min. PCR was performed according to methods published previously (14), on
cDNA using 0.25 mM concentrations of primer pairs specific for CD95L

Fig. 1. Antiviral therapy results in decreased tumor burden in HIV-related BL. A,
Wright Giemsa stain of iliac crest biopsies performed on day 0 (upper panel) and day 15
(lower panel) in a patient with HIV-related, EBV-positive BL. B, tumor burden and tumor
lysis were monitored by daily measurement of serum LDH after AZT and IFN-a antiviral
therapy. f, LDH concentration in the serum of a patient with BL (BL-5); F, LDH levels
from a patient with IBL (IBL-3).
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Fig. 2. AZT induces CD-95 expression and apoptosis in BL-5 but
not IBL-3 and IBL-4. A, BL-5 cells were treated for 48 h with
titrating doses of AZT and analyzed for apoptosis by propidium
iodide/annexin flow cytometry. B, dose-response of CD95 expression by AZT. BL-5 was treated with AZT for 40 h at the indicated
concentrations, and CD95 expression was monitored by flow cytometry. The data are representative of three independent experiments.
C, cells from BL-5 (left panel) cultured for 48 h in the presence
(solid line) or absence (dashed line) of AZT 5 mg/ml and analyzed
for CD95 expression by flow cytometry. Dotted line, isotype control
(mouse IgG-1). Cells from IBL-3 (center panel) and IBL-4 (right
panel) were cultured in the presence (solid line) or absence (dashed
line) of AZT 100 mg/ml, and CD95 expression was analyzed by flow
cytometry [dotted line, isotype control (mouse IgG-1) in BL-5 and
IBL-4].

(59 primer, 59-CGCCACCACTGCCTCCACTA-39; 39 primer, 59-CTTCCCCTCCATCATCACCA-39) containing 0.25 mM of each deoxynucleotide
triphosphate, 10 mM Tris (pH 9.0), 5 mM KCl 0.1%, 1.5 mM MgCl2 and 0.2
unit Taq DNA for 35 cycles (denaturation for 1.5 min at 94°C, annealing for
1.5 min at 60°C, and extension for 1 min at 72°C). PCR products were
equalized using amplified product of the housekeeping gene glyceraldehyde3-phosphate dehydrogenase as a standard. ELISA for CD95L was performed
on control cells and cells treated with IFN-a (1000 units/ml) and cultured for
48 h using the MBL Biotechnology ELISA kit (Watertown, MA).
PCR Screening for EBV and HHV-8. DNA was tested for the presence
of the EBV BMLF1 as described previously (15). The two primers are
59-CACCACCTTGTTTTGACGGG-39 and 59-GTCAACCAACAAGGACACAT-39, which amplify a fragment of 304 bp. The amplified products were
then analyzed on a 1% agarose gel. Amplification of the KS 330233 bp
fragment on DNA extracted from tumor samples was performed on malignant
lymphomatous effusions (suspected PEL), using HHV-8-specific primers (59-

AGCCGAAAGGATTCCACCATT-39 and 59-TCCGTGTTGTCTACGTCCAGA-39) and published conditions (4), and analyzed on a 1% agarose
ethidium bromide gel.
Western Blot Analysis. Cell lysates prepared from primary tumor cells
(3 3 106) in RIPA buffer were resolved on a 12% SDS polyacrylamide gel.
Proteins were transferred to nitrocellulose and after blocking with nonfat dry
milk, immunoblot analyses were performed using a hamster monoclonal IgG
antibody against human BCL-2 (PharMingen), followed by a mouse antihamster IgG secondary antibody (PharMingen). This was followed by a horse
radish peroxidase conjugate sheep antimouse IgG at 1:2000 dilution (ECL;
Amersham, Arlington Heights, IL). For c-myc, caspase-3, and PARP immunoblots, we used PharMingen antibodies followed by the ECL detection
system (Amersham). LMP-1 immunoblotting was performed with a Dako
(Glostrup, Denmark) antibody cocktail that detects LMP-1 (epitopes CS 1– 4).
When using this antibody, typically 2 bands appear in LMP-1-positive Western
blots (16).

Fig. 3. AZT induces apoptosis in BL. AZT
activates caspase 3. BL-5 and IBL-4 cells were
treated with AZT 5 mg/ml over a 2-day time course.
Lanes 1–7, time-dependent caspase 3 activation in
BL-5 cells. Lanes 8 –11, only uncleaved caspase 3
in AZT-treated IBL-4 cells. AZT induced maximal
formation of the activated cleaved caspase 3 by
30 – 40 h in BL-5.
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AZT Phosphorylation Assay. Intracellular levels of phosphorylated AZT
were measured using published methods (17). Cells were plated out in 24-well
plates at 106 cells/ml/well and incubated with 5 mg/ml [3H]AZT. After 24 h of
incubation, cells were harvested and washed with PBS twice. Cell pellets were
extracted with cold 65% methanol on ice for 30 min and spun at 1500 rpm for
5 min. The supernatants were collected and applied to high-performance liquid
chromatography for measurements of the monophosphate, diphosphate, and
triphosphate forms of AZT.

RESULTS
Clinical Activity of AZT and IFN-a in AIDS NHL. We
reported previously that AIDS BL patients responded to parenteral
AZT and IFN-a therapy with gradual regression of lymphoma and
tumor lysis over a 2-week period. Response was demonstrated by
regression of lymphadenopathy, splenomegaly, and leukemia (data
not shown). In contrast, AIDS IBL patients worsened on AZT and
IFN-a therapy and required conventional chemotherapy within
4 –5 days (11). Fig. 1A demonstrates the clearance of lymphoma
involving the bone marrow in a patient with EBV-positive BL after
2 weeks of parenteral AZT and IFN-a therapy. To test whether
selective antiviral-induced apoptosis was the mechanism of this
disparate response, we isolated primary tumor cells prior to AZT
and IFN-a therapy from a BL patient (BL-5) and from a patient
with IBL (IBL-3). Clinically, these patients displayed opposite
responses to AZT and IFN-a. LDH, a marker of tumor burden,
declined in patient BL-5 during AZT and IFN-a treatment, coinciding with marked regression of tumor burden (Fig. 1B). IBL-3
did not respond and clinically worsened over the first 4 days of
therapy. Because we typically had seen objective tumor regression
within this time period in responsive patients, AZT and IFN-a
therapy was stopped for ethical reasons.
In Vitro Induction of Apoptosis and CD95 Expression Correlates with Clinical Response. We investigated whether the clinical
response to AZT and IFN-a correlated with the induction of apoptosis
in cultured tumor cells. BL-5 and IBL-3 cells were cultured for 48 h
in AZT and apoptosis was measured by annexin V flow cytometry.
AZT induced apoptosis in a time- and dose-dependent manner in
BL-5 (Fig. 2A). AZT had no effect on IBL-3 cells, and IFN-a did not
increase apoptosis in BL-5, IBL-3, or IBL-4 (data not shown).
Because previous work suggested that conventional chemotherapeutic agents induce apoptosis in sensitive cells through CD95
(also known as Fas or APO-1) signaling (18), we investigated
whether AZT up-regulates this proapoptotic molecule on BL-5.
CD95 expression, as measured by flow cytometry, was induced on
BL-5 cells in a dose-dependent manner (Fig. 2B). CD95 was not
induced on IBL-3 or IBL-4 cells by even higher doses of AZT (100
mg/ml; Fig. 2C). CD95 induced by AZT also was competent to
signal apoptosis by agonistic CD95 cross-linked antibody (clone
DX-2; data not shown).
Induction of Apoptosis by AZT Is Caspase Dependent. Cleavage of caspase-3 and other protein substrates are events that occur in
a cell committed to apoptosis (19, 20). AZT, in a time-dependent
manner, induced cleavage of caspase-3 into the active protease in
BL-5 cells. In contrast, caspase 3 cleavage was not detected in IBL-4
cells treated with AZT (Fig. 3). AZT treatment of BL-5 also was
associated with cleavage of PARP, as detected by Western blotting.
PARP cleavage in BL-5 was blocked by the broad spectrum caspase
inhibitor Boc-D-fmk (data not shown).
Induction of Apoptosis in HHV-8-positive PEL by AZT and
IFN-a. We studied the effects of AZT on the HHV-8-positive PEL
cell line, BCBL-1. Although AZT also induced CD95 on BCBL-1,
apoptosis was much less than that observed in BL-5. We therefore
studied whether the CD95 induced by AZT was functional by using

Fig. 4. BCBL-1 undergoes apoptosis in response to AZT and IFN a. A, induction of
CD95L-mediated cytotoxicity is potentiated by AZT. BCBL-1 cells were cultured in the
presence (F) or absence (f) of AZT (10 mg/ml) for 48 h. Cells were then 51Cr-labeled and
cocultured with EL-4 cells stably transfected with murine CD95L (EL4-mfl) for 4 h.
Specific 51Cr release was measured by determining the cpm released into the culture
supernatant. The data are presented as the means of triplicate samples and represent two
independent experiments. B, IFN-a potentiates apoptosis in AZT-treated BCBL-1.
BCBL-1, BL-5, and IBL-4 cells were cultured for 72 h in medium, IFN-a (1000 units/ml),
AZT (5 mg/ml), or AZT (5 mg/ml) and IFN a (1000 u/ml) together and assayed for
apoptosis by annexin V-FITC staining and FACS analysis. Bars, SD. C, IBL-4 and BL-5
are sensitive to Adriamycin. IBL-4 and BL-5 cells were cultured in medium or Adriamycin 0.5 mg/ml for 48 h, and apoptosis was measured by annexin V staining. Data are
presented as the percentage of annexin-positive cells; bars, SD.

EL-4 murine lymphoma cells transfected with CD95 ligand (EL4mFL) as effector cells in a cellular cytotoxicity assay. EL4-mFL
transfectants induced significant specific lysis of BCBL-1 cells pretreated with AZT compared with nontreated BCBL-1 target cells (Fig.
4A). This cellular cytotoxicity was specific for the CD95 pathway
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higher levels of CD95L then control PBMCs, as measured by ELISA
(data not shown).
Fas Blockade Does Not Inhibit AZT and IFN a-mediated Apoptosis. Although in BCBL-1, CD95 was induced by AZT and
CD95L by IFN-a, the cytopathic effect of this combination occurred
in both BL-5 and BCBL-1, despite CD95 receptor blockade by the
anti-CD95 antibody, Zb4 (Fig. 6). Zb-4 did block EL-4mFas-L transfectants directed against Fas-positive BCBL-1 cells as well as agonist

Fig. 5. IFN-a induces CD95L. Normal PBMCs, BCBL-1, BC-1, and BL-5 cells were
treated as indicated in the figure for 5 h. AZT treatment was performed at 100 mg/ml
and/or IFN-a 1000 units/ml. Cells were then lysed, and total RNA was extracted and
hybridized with a DNA probe specific for CD95L. gapdh, glyceraldehyde-3-phosphate
dehydrogenase.

Fig. 6. CD95 receptor blockade does not inhibit AZT and IFN-a-mediated apoptosis.
BCBL-1 and BL-5 cells were treated for 48 h with AZT (5 mg/ml) and IFN-a (1000 u/ml)
in the presence or absence of anti-CD95 blocking antibody ZB4. Apoptosis was measured
by FACS analysis of annexin V-FITC staining.

because the EL4 cells were transfected with only CD95L. In addition,
EL4 mock transfectants did not lyse BCBL-1, and EL4-mFL cytotoxicity against AZT treated BCBL-1 was blocked by CD95 blocking
antibody (clone ZB4; data not shown). This demonstrated that AZT
also induces functional CD95 on BCBL-1.
Because IFN-a is included in our antiviral chemotherapy clinical
protocol, we characterized the response of BCBL-1, BL-5, and the
IBL-4 lymphoma line to treatment with AZT, IFN-a, or both agents
together. BL-5 was sensitive to AZT-induced apoptosis, and IFN-a
had no additive effect. BCBL-1 was relatively resistant to apoptosis
induced by AZT alone but underwent significantly increased apoptosis upon treatment with both AZT and IFN-a. IBL-4 cells were
resistant to either agent alone or in combination (Fig. 4B). A similar
synergy between AZT and IFN-a-induced apoptosis was observed in
another HHV-8-positive PEL cell line, BC-3 (data not shown). Resistance to AZT in IBL-4 cells did not correlate with resistance to
Adriamycin. Both BL-5 and IBL-4 were quite sensitive to apoptosis
induced by Adriamycin (Fig. 4C).
IFN-a Induces CD95L Expression. Although AZT alone induced
functional CD95 expression in BCBL-1, apoptosis was markedly
enhanced by the addition of IFN-a. We therefore studied whether
IFN-a could induce CD95L. Primary lymphoma BL cells (BL-5),
PEL lymphoma cell lines (BCBL-1 and BC-1), and PBMCs from a
normal donor cultured in the presence of IFN-a were assayed for
CD95L expression using semiquantitative reverse transcription-PCR.
CD95L transcripts were significantly induced in the PEL cell lines
BCBL-1 and BC-1 but not in BL-5. CD95L was also strongly induced
in PBMCs by IFN-a (Fig. 5). IFN-a treated PBMCs also expressed

Fig. 7. AZT selectively induces apoptosis in EBV-positive, BCL-2-negative cells. A,
EBV-positive Burkitt’s cells (BL-5, BL-3, SM-1, Daudi, Namalwa, and P3HR-1). EBVnegative lymphomas (BJAB, Ramos, D6, and BL-6) and immunoblastic lymphoma cells
(IBL-3 and IBL-4) were treated for 48 h in medium or AZT 5 mg/ml. Apoptosis was
measured by annexin V flow cytometry. Data are presented as the percentage of apoptotic
cells in each fraction. B, baseline expression levels of BCL-2 were determined by Western
blot in each lane. Lane 1, BL-5; Lane 2, BL-3; Lane 3, Daudi; Lane 4, P3HR-1; Lane 5,
SM-1; Lane 6, Namalwa; Lane 7, BJAB; Lane 8, Ramos; Lane 9, D-6; Lane 10, BL-6;
Lane 11, IBL-3; Lane 12, IBL-4. LMP-1 Western blots were performed on all EBVpositive lines. C, BL-5 cells transfected with BCL-2 (BL-5-BCL-2) were treated for 48 h
in medium or AZT 5 mg/ml, and apoptosis was measured by annexin V staining. Bottom
panel, BCL-2 expression levels for IBL-4 and BL-5-BCL-2.
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DISCUSSION

Fig. 8. AZT-induced apoptosis correlated with intracellular AZT-MP levels. AZTsensitive (P3HR-1 and BL-5) and resistant (Ramos and IBL-4) cell lines were cultured in
the presence of tritiated AZT for 24 h. Intracellular levels of AZT-MP, DP, or TP were
determined by high-performance liquid chromatography. Data are presented as nanograms
of each form of phosphorylated AZT per million cells. Bars, SD.

anti-Fas antibody CH-11 directed against H-9 cells (data not shown).
This indicates that the mechanism of apoptosis activated by these
agents is more complex than induction of a CD95/CD95L interaction,
although if multiple apoptosis pathways are activated by AZT and
IFN-a, blockade of one pathway may show no inhibition in overall
cytotoxicity (21).
Differential Apoptosis of NHL Subtypes Induced by AZT. To
determine whether apoptosis induced by AZT targets certain types
of tumor cells, we tested a panel of B-cell lymphomas including
lines derived from AIDS patients and published lines. All AZTsensitive primary cells and lines were EBV positive (BL-5, BL-3,
SM-1, Daudi, P3HR-1, and Namalwa). Resistance to AZT correlated with the level of BCL-2 detected by Western blot in EBVpositive lines (IBL-3 and IBL-4) or the absence of EBV (BJAB,
Ramos, D6, and BL-6). Both IBL-3 and IBL-4 also expressed high
levels of LMP-1 protein (Fig. 7, A and B). An EBV-negative T-cell
line, H-9, and B95– 8, an EBV-infected line that expresses BCL-2
and LMP-1, were also resistant to AZT (data not shown). To study
whether BCL-2 expression could change an AZT-sensitive line to
a resistant phenotype, we transfected BL-5 with BCL-2. As demonstrated in Fig. 7C, BL-5-BCL-2 cells were much more resistant
to AZT-mediated apoptosis.
Intracellular AZT-MP Levels Correlate with Sensitivity to
AZT-mediated Apoptosis. Intracellular AZT is phosphorylated to
mono-, di-, and triphosphate. The triphosphate (AZT-TP) competes
with TTP (TTP-TP) for utilization by HIV reverse transcriptase,
thereby inhibiting viral replication. However, AZT monophosphate
(AZT-MP) is believed to be a cytotoxic intermediate (22, 23). We
therefore investigated whether the cytopathic effect of AZT in cells
correlated with the intracellular levels of AZT-MP. We cultured the
AZT-sensitive (BL-5 and P3HR-1) and -resistant (IBL-4 and Ramos)
lines in the presence of tritiated AZT 5 mg/ml for 24 h and measured
the relative levels of the phosphorylated forms of AZT by highperformance liquid chromatography. A markedly higher level of
AZT-MP was detected in the sensitive P3HR-1 and BL-5 lines than in
the resistant IBL-4 and Ramos lines (Fig. 8). This suggests that
AZT-MP may preferentially accumulate in certain EBV-positive lymphoma cells sensitive to AZT-mediated apoptosis.

AIDS NHL grows so rapidly that patients often present with moderate to severe tumor lysis syndrome. Although apoptotic death of
tumor cell lines treated with chemotherapeutic agents has been demonstrated in vitro (18), in the clinical setting cytotoxic chemotherapy
often exacerbates necrotic cell death and tumor lysis syndrome, resulting in further release of proteolytic enzymes and tissue damage
(24). This complication is particularly common in aggressive lymphomas; therefore, a therapy that induces apoptosis of these tumors in
vivo would be of great value. The gradual regression of lymphoma and
resolution of tumor lysis syndrome of our AIDS BL patients treated
with AZT/IFN-a suggested to us that their clinical response was
through an apoptotic rather than a necrotic type of cellular death.
We found that EBV-positive BL cells from these AIDS patients
responded in vitro to AZT by undergoing apoptosis. AZT-sensitive
cells underwent apoptotic membrane changes, cleaved their PARP,
and died through a caspase-dependent pathway. AZT also induced
elevated expression of CD95 competent to signal apoptosis when
triggered by an agonistic antibody. Thus, one mechanism of the
clinical response observed in these patients may be through upregulation of CD95 that is subsequently signaled by circulating activated tumor-specific CTLs expressing CD95L, resulting in apoptotic
death. Surprisingly, only EBV-positive lymphomas were sensitive to
AZT-mediated apoptosis. EBV-negative Burkitt’s lines (BJAB, D6,
and Ramos), an AIDS-related EBV-negative BL (BL-6), and another
T-cell line (H9) were resistant to AZT. It is possible that EBV plays
a role in susceptibility to AZT.
Although we did not treat any PEL patients with AZT and IFN-a,
AZT induced apoptosis in HHV-8-positive PEL cell lines that was
markedly potentiated by IFN-a. The induction of CD95L by IFN-a in
these cells may partially explain why these lymphoma lines were
sensitive to the combination of these agents. If CD95 is up-regulated
by AZT in tumor cells in vivo, IFN-a may increase the expression of
Fas-L in cytotoxic cells. IFN-a is an endogenous cytokine, and one of
its functions may be to up-regulate certain death receptor ligands such
as CD95L in response to stimuli such as viral infections. AZT- and
IFN-a-induced apoptosis occurred in vitro despite the presence of
CD95 blocking antibodies. This suggests that CD95 up-regulation
may be a marker for lymphomas that are responsive to AZT/IFN-a
therapy but are not the sole pathway of apoptosis. However, if
circulating BL cells express CD95 after parenteral AZT therapy,
clearance by IFN-a-stimulated CD95L-bearing cells may be enhanced.
The EBV-positive AIDS lymphomas that overexpressed BCL-2
were resistant to AZT-mediated apoptosis. Overexpression of BCL-2
in a sensitive lymphoma line also rendered it resistant to AZT.
Because BCL-2 may be expressed at high levels in AIDS NHL, this
therapy may not be effective in EBV-positive lymphomas that overexpress this antiapoptotic protein. A recent pathological review of
AIDS NHLs indicates that BCL-2 expression is less frequent in AIDS
BL (9); however; most AIDS BLs are also EBV negative (8). In
contrast, endemic BL is virtually always EBV positive (25, 26);
therefore AZT or AZT and IFN-a may be quite active in this lymphoma subtype. Our data also support this because AZT was markedly
proapoptotic in lymphoma lines derived from endemic BL.
AZT, originally developed as a chemotherapeutic agent, has activity in adult T-cell leukemia (27) but has been recently used almost
exclusively as an antiretroviral agent. Its adverse clinical effects are
thought to be related to mitochondrial toxicity (28). Our data demonstrated a correlation between susceptibility to AZT and intracellular
accumulation of AZT-MP. The factors responsible for the marked
increase in AZT-MP in EBV-positive BLs, P3HR-1, and BL-5, are
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unclear but could involve phosphorylation by herpesvirus kinases. It
would be necessary to study AZT-MP levels in tumor cells taken from
patients on therapy, as well as more cell lines, to determine whether
this occurs in vivo or is exclusively an in vitro phenomenon. If
apoptosis was triggered after intracellular accumulation of AZT-MP,
this would explain why Fas receptor blockade did not inhibit apoptosis in vitro.
In summary, our data indicate there are at least three different
responses to the effects of AZT or AZT and IFN-a in patients with
high-grade B-cell lymphomas: (a) EBV-positive lymphomas that express low levels of BCL-2, up-regulated CD95, and underwent apoptosis upon exposure to AZT. Patients with these types of tumor may
benefit from these agents, perhaps given in conjunction with or prior
to standard chemotherapy; (b) EBV-positive lymphomas that express
high levels of BCL-2 (and LMP-1) or EBV-negative lymphomas were
resistant to AZT (or AZT and IFN-a). Patients with these types of
tumors might not benefit from these agents; (c) HHV-8-positive PEL
cells (BCBL-1 and BL-3) were minimally sensitive to AZT and
required IFN-a for a significant apoptotic effect. Because we did not
treat PEL patients with these agents, we can say little of their potential
efficacy in this disease. Although these findings are based on a limited
number of samples, the data suggest that some herpesvirus-associated
lymphomas may be responsive to AZT and IFN-a. Herpesvirusassociated lymphomas are also seen in a variety of clinical scenarios,
including hereditary immunodeficiencies and iatrogenic immunosuppression after organ transplantation (29, 30). To confirm these findings, more isolates need to be studied. However, if these observations
are valid, they can be translated into clinical trials that use antivirals
as part of a regimen. Anticancer agents that induce tumor apoptosis in
vivo would also likely lessen patient morbidity from complications of
tumor lysis caused by standard chemotherapy agents.
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